Labcorp, a global laboratory services company with a significant presence in diagnostics and drug development, has received approval from the U.S. Food and Drug Administration for its PGDx Elio Tissue Complete CDx — a companion diagnostic test that uses next-generation sequencing to detect specific BRAF V600E and V600K variants in tumor tissue from patients with advanced melanoma. The goal of this innovation is to help clinicians determine which individuals may be eligible for treatment with FDA-approved BRAF inhibitors or BRAF/MEK inhibitor combination therapies.
Melanoma, particularly at stage IV, has a historically low five-year survival rate of approximately 16%, making timely and accurate molecular profiling critical for guiding treatment decisions. Labcorp's companion diagnostic test addresses that need by providing a standardized, scalable kit-based solution that can be implemented directly within hospitals and health systems.
Image Credit: Labcorp
What's Driving This Trend
- Kit-based Genomic Testing
- Standardized sequencing kits are shifting advanced molecular profiling into hospital labs, creating room for faster oncology decision-making and more distributed diagnostic capacity.
- Therapy-matched Diagnostics
- Companion tests tied to specific drug eligibility are strengthening the connection between diagnostics and treatment pathways, opening new value models across precision medicine.
- Scalable Tumor Profiling
- Broadly deployable tissue-based genomic assays are reducing reliance on centralized specialty labs while improving access to biomarker-guided cancer care.
Who This Affects Most
- Precision Oncology
- Molecularly targeted cancer care is expanding as approved diagnostics identify patients most likely to benefit from specific therapies.
- Clinical Diagnostics
- FDA-cleared companion tests are elevating diagnostic labs into strategic partners for treatment selection, reimbursement alignment, and care standardization.
- Pharmaceutical Development
- Drug developers are increasingly dependent on validated biomarker tests to support targeted therapy adoption and improve clinical trial segmentation.
